Department of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani, 127021, India.
Department of Pharmaceutical Sciences, Gurugram University, Gurugram, India.
Recent Pat Nanotechnol. 2024;18(4):395-414. doi: 10.2174/1872210517666230613154847.
BACKGROUND: Lung cancer is a foremost global health issue due to its poor diagnosis. The advancement of novel drug delivery systems and medical devices will aid its therapy. OBJECTIVE: In this review, the authors thoroughly introduce the ideas and methods for improving nanomedicine- based approaches for lung cancer therapy. This article provides mechanistic insight into various novel drug delivery systems (DDSs) including nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, niosomes, and nanoemulsions for lung cancer therapy with recent research work. This review provides insights into various patents published for lung cancer therapy based on nanomedicine. This review also highlights the current status of approved and clinically tested nanoformulations for their treatment. METHODOLOGY: For finding scholarly related data for the literature search, many search engines were employed including PubMed, Science Direct, Google, Scihub, Google Scholar, Research Gate, Web of Sciences, and several others. Various keywords and phrases were used for the search such as "nanoparticles", "solid lipid nanoparticles", "liposomes", "dendrimers", "niosomes", "nanoemulsions", "lung cancer", "nanomedicine", "nanomaterial", "nanotechnology", "" and "". The most innovative and cutting-edge nanotechnology-based approaches that are employed in pre-clinical and clinical studies to address problems associated with lung cancer therapies are also mentioned in future prospects. A variety of problems encountered with current lung cancer therapy techniques that frequently led to inadequate therapeutic success are also discussed in the end. CONCLUSION: The development of nanoformulations at the pilot scale still faces some difficulties, but their prospects for treating lung cancer appear to be promising in the future. Future developments and trends are anticipated as the evaluation comes to a close.
背景:由于肺癌诊断效果不佳,它是一个首要的全球健康问题。新型药物输送系统和医疗器械的进步将有助于其治疗。
目的:在这篇综述中,作者全面介绍了改进基于纳米医学的肺癌治疗方法的思路和方法。本文深入探讨了各种新型药物输送系统(DDS),包括用于肺癌治疗的纳米粒、固体脂质纳米粒、脂质体、树枝状大分子、非诺贝特囊泡和纳米乳剂,以及近期的研究工作。本文还提供了基于纳米医学的肺癌治疗的各种专利的见解。本文还重点介绍了已批准并在临床上进行测试的纳米制剂的当前状态及其治疗用途。
方法:为了在文献检索中找到相关学术数据,使用了许多搜索引擎,包括 PubMed、Science Direct、Google、Scihub、Google Scholar、Research Gate、Web of Sciences 等。使用了各种关键词和短语进行搜索,例如“nanoparticles”、“solid lipid nanoparticles”、“liposomes”、“dendrimers”、“niosomes”、“nanoemulsions”、“lung cancer”、“nanomedicine”、“nanomaterials”、“nanotechnology”、“”和“”。还提到了在临床前和临床研究中用于解决与肺癌治疗相关问题的最具创新性和最先进的基于纳米技术的方法。还在最后讨论了当前肺癌治疗技术中经常导致治疗效果不佳的各种问题。
结论:虽然在试点规模上开发纳米制剂仍面临一些困难,但它们在未来治疗肺癌方面的前景似乎很有希望。随着评估的结束,预计未来会有更多的发展和趋势。
Pharm Nanotechnol. 2024
Curr Pharm Des. 2017
Adv Exp Med Biol. 2016
Curr Pharm Des. 2020
Chem Biol Interact. 2019-6-18
Front Immunol. 2025-3-17
Viruses. 2025-2-1
Recent Adv Drug Deliv Formul. 2024-12-9